Investigational drug · Phase 2
SAR445877
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Solid Tumor, Gastric Cancer, Oesophageal Carcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 20, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "SAR445877"
First trial start
2022
Nov 29, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SAR445877", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumor
- Gastric Cancer
- Oesophageal Carcinoma
Approved drugs for the same conditions: Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "SAR445877" as an intervention, largest first.
SanofiSanofi (SNY)
NCT05584670 · 542 participants (planned) · Start Nov 29, 2022 · Primary completion Jan 19, 2027
Drug: SAR445877; Cetuximab and 4 more · For: Solid Tumor
Sites: Newark, Delaware; Iowa City, Iowa; Westwood, Kansas · 22 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT07500298 · 41 participants (planned) · Start May 20, 2026 · Primary completion Dec 27, 2030
Drug: SAR445877; FOLFOX6 and 1 more · For: Phase 1; SAR445877; FOlfox6 and 4 more
Sites: Houston, Texas
SanofiSanofi (SNY)
NCT07692204 · 30 participants (planned) · Start Jul 1, 2026 · Primary completion Aug 2, 2028
Drug: SAR445877 · For: Gastric Cancer; Oesophageal Carcinoma
Sites: Shanghai, China
- A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung CancerRecruiting
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT07133425 · 29 participants (planned) · Start Nov 6, 2025 · Primary completion Feb 1, 2028
Drug: SAR445877 · For: Non-Small Cell Lung Cancer; ICI-refractory
Sites: Houston, Texas
Newest research
PubMed records naming it or its code names, newest first.
- PD-1-targeted IL-15 mutein activates CD8+ and CD4+ T cells in infection and cancer.
Pratumchai I, Bernardo M, Tessier J, et al. · JCI Insight 2026
Also in development for Solid Tumor
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.